Working… Menu
Trial record 1 of 1 for:    NCT02601950
Previous Study | Return to List | Next Study

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02601950
Recruitment Status : Recruiting
First Posted : November 11, 2015
Last Update Posted : September 24, 2021
Information provided by (Responsible Party):
Epizyme, Inc.